Elezanumab is a monoclonal antibody designed to target and neutralize Repulsive Guidance Molecule A (RGMA), a protein involved in inhibiting neuronal growth and repair in the central nervous system. Its primary application lies in the potential treatment of neurodegenerative and neurologic disorders, particularly those involving impaired neural regeneration, such as spinal cord injury and multiple sclerosis. By blocking RGMA, elezanumab may promote axonal regeneration and enhance neural plasticity, supporting functional recovery after injury. It has been investigated in clinical trials for improving motor function in patients with acute spinal cord injury. The antibody’s mechanism supports neuroprotection and repair, making it a promising candidate for conditions where current treatment options are limited. Research is ongoing to explore its efficacy in other CNS disorders with a regenerative component.